Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited develops epigenetics-based diagnostics through its Nucleosomics platform, which measures nucleosomes in blood and other bodily fluids. The company’s Nu.Q® product portfolio spans human diagnostics and monitoring for cancer, sepsis, trauma biomarker research and other disease areas, as well as veterinary oncology through Nu.Q® Vet assays.
VNRX news covers clinical publications and assay-development milestones, commercialization of Nu.Q® tests, veterinary cancer-test development, recombinant nucleosome products under rNuQ™, licensing and distribution activity, financial results, non-dilutive funding, equity financing and NYSE American listing-compliance matters. Volition’s research and development activities are centered in Belgium, with additional operations in the United States and London.
VolitionRx (NYSE AMERICAN: VNRX) received a NYSE American notice dated February 6, 2026, that it is not in compliance with stockholders' equity listing standards in Sections 1003(a)(i)-(iii).
The company must file a compliance Plan by March 8, 2026 to regain compliance by August 6, 2027, or face potential delisting proceedings; shares will trade with a ".BC" designation meanwhile.
Volition (NYSE: VNRX) sponsored a symposium at the European Hidradenitis Suppurativa Foundation conference in Malta on Feb 5, 2026, presenting clinical data for the Nu.Q® NETs plasma assay in Hidradenitis Suppurativa (HS).
The company highlighted a recently released cohort study suggesting Nu.Q® NETs can classify HS severity and may guide treatment selection; a related poster was presented Feb 4. The assay is CE‑Marked and commercially available across 27 EU member states, three EEA countries, and the U.K., and Volition cited a $3.8 billion total addressable market.
Volition (NYSE AMERICAN: VNRX) is preparing a reimbursement submission for its Nu.Q® Cancer assays to French government agencies, supported by Hospices Civils de Lyon (HCL). The dossier will run alongside clinical certification at HCL under the RIHN framework, with admissibility review followed by a reimbursement decision expected within five months.
The company cites ~50,000 new lung cancer diagnoses and ~65,000 five-year prevalence in France and anticipates routine clinical use in France by Q4 2026 while pursuing international partnerships and licensing opportunities.
Volition (NYSE: VNRX) announced a clinical study showing use of its Nu.Q® NETs assay to manage Hidradenitis Suppurativa (HS), a chronic immune-mediated disease affecting ~1% of the global population. The release notes the Nu.Q® NETs assay is CE‑Marked and commercially available across 27 EU member states, 3 EEA countries (Iceland, Liechtenstein, Norway) and the U.K.
The company cites a $3.8 billion Total Addressable Market (Data on File: Volition TAM Model) and says the test may help classify HS severity, guide treatment decisions and act as a surrogate marker for response, specifically noting circulating H3.1‑nucleosomes as a candidate blood marker. The paper is noted as available on medRXIV and includes prior related publications.
Volition (NYSE: VNRX) announced new laboratory partnerships to expand access to its Nu.Q® Vet Cancer test in the U.S. and Asia. Midwest Veterinary Laboratory will offer the test across all 50 U.S. states beginning February 2026. Bioguard will offer the test via its Animal Health Diagnostic Center, described as the first certified ISO/IEC 17025 animal disease testing laboratory in Taiwan and China. Management highlighted integrating Nu.Q® into annual or senior wellness exams to enable earlier cancer detection in dogs. Volition cited a Total Addressable Market for canine screening of about $100 million for the U.S., Europe and Japan, rising to just under $150 million with China.
VolitionRx (NYSE AMERICAN: VNRX) is sponsoring an industry symposium at the Veterinary Meeting and Expo (VMX) in Orlando, Florida, with a presentation on Monday, January 19, 2026 at 2:45 PM EST by Dr. Sue Ettinger titled "Utilizing the Nu.Q® Vet Cancer Test in Practice."
The company said its Volition Veterinary Diagnostics Development team will staff booth 2243 during the conference, which draws about 20,000 veterinary professionals. Management highlighted using the Nu.Q® Canine Cancer Test during annual or senior-wellness exams to aid earlier cancer detection and support timely care decisions for pet owners.
Volition (NYSE AMERICAN: VNRX) entered an amended and restated securities purchase agreement with Lind Global Asset Management XII LLC to receive $2.0 million gross proceeds in exchange for a senior secured convertible promissory note with $2.4 million principal (the 2026 Note) and a five-year warrant to buy 7,000,350 common shares at $0.5714 per share. The company will pay a $70,000 commitment fee by deduction from the funding. The 2026 Note accrues no interest and is repayable in 18 monthly installments of $133,333, convertible at $0.5714, and the company must file a resale registration within 30 days of closing.
Volition (NYSE AMERICAN: VNRX) reported clinical study results for the Nu.Q® Vet Feline assay showing 100% specificity and detection of over 80% of feline lymphomas, supporting development of a blood-based liquid biopsy for cats. The company cites a U.S. population of 73.8 million pet cats, ~1-in-5 cats estimated to develop cancer, >18 million senior cats (8+), and a North American veterinary oncology market projected at $1.77 billion by 2025. Management expects a peer-reviewed publication, a $5 million contractual milestone, and commercial rollout via existing lab and point-of-care channels.
Volition (NYSE AMERICAN: VNRX) issued its Business Review 2025 outlining commercial, clinical, and IP milestones as it commercializes the Nu.Q platform.
Key points: first clinical order for the Nu.Q Cancer assays for lung cancer, inclusion of the Nu.Q NETs assay in a government-backed ~$7.3 million French sepsis evaluation, first revenue from the CE‑Marked Nu.Q NETs automated assay, signed human‑licensing agreements with Werfen and Hologic, and a payable $5 million contractual milestone tied to feline lymphoma results.
Scientific advances highlighted include Capture-Seq™ with 180-fold (18,000%) ultrashort DNA enrichment and peer‑reviewed NETs data (1,713 patients) supporting clinical utility.
Volition (NYSE: VNRX) announced a preprint describing Capture-Seq™, a method that physically enriches ultrashort transcription factor–bound cfDNA for liquid biopsy. The company reports a 180-fold (18,000%) enrichment, removal of ~99% background DNA, and two patent-pending separation technologies. In a small training cohort of 70 subjects (49 cancer patients), analysis reportedly achieved 100% sensitivity and 100% specificity. Volition projects a $23 billion annual TAM and is seeking commercial partners; results require independent validation in larger studies.